Decades After Menopause, Human Ovaries Are Still Remodeling
Postmenopausal ovaries remain molecularly active and change with age.
For many years, scientists have dismissed the postmenopausal ovary as an inactive biological remnant, similar to the appendix.
However, a study from Northwestern University and the Buck Institute revealed that human ovaries remain surprisingly dynamic, undergoing continuous molecular remodeling decades after menopause.
What happens to the ovaries after menopause?
The human ovary ages faster than almost any other organ. Its reserve of follicles depletes over time, triggering menopause around age 50.
As women are now living for decades after menopause, understanding postmenopausal biology is a pressing issue. The ovary also does not operate in isolation; it communicates with other aging networks, including the brain and bones.
“In the ovary, we reach a point of no return with respect to fertility in which it's no longer producing eggs, and I would venture to say most people assume those ovaries are just sitting there doing nothing,” said co-corresponding author Dr. Francesca Duncan, associate professor of reproductive science in medicine at Northwestern University Feinberg School of Medicine, and associate professor in residence at the Buck Institute. “But that's what makes this study very different”.
Researchers previously knew very little about the molecular state of healthy ovaries following reproductive cessation. Past studies relied on small sample sizes or focused on younger, premenopausal tissues.
Duncan and the team mapped the proteomic landscape of healthy human ovaries across the postmenopausal lifespan from ages 50–75.
Proteomic shifts in the ovary decades after menopause
Healthy ovarian tissue was analyzed from 28 postmenopausal participants divided into three age groups: 50–59 years, 60–69 years, and 70 years and older. Using data-independent acquisition mass spectrometry, the team quantified 5,812 distinct protein groups across all samples. They paired this with statistical models, pathway mapping, tissue staining, and comparisons against cellular senescence and cancer datasets.
“When we analyzed the data in multiple different statistical ways, what became clear across all these methodologies is that the ovary was not stagnant,” said co-corresponding author Dr. Birgit Schilling, the director of the Mass Spectrometry Core and a professor at the Buck Institute. Schilling also serves on the Technology Networks Scientific Advisory Board. “In fact, over the decades, there were quite dramatic differences in terms of some proteins’ levels would go up with age, and some proteins’ levels would go down, which tells us this organ is quite dynamic,” she said
As women age past 70, the human ovary actively sheds structural and keratin proteins while ramping up immune signaling, inflammatory pathways, and extracellular matrix remodeling. Specific shifts were highlighted, including decreased FABP5 and increased HS6ST2. Key matrix remodelers, like WNT4 and fibromodulin, also shifted with age and were validated via tissue staining.
FABP5 (Fatty acid-binding protein 5): A protein involved in lipid handling that decreases in abundance as postmenopausal ovaries age.
HS6ST2 (Heparan-sulfate 6-O-sulfotransferase 2): A sugar-modifying enzyme linked to tissue structure and disease progression that increases in abundance with age.
WNT4: A secreted signaling protein crucial for ovarian development and tissue organization that increases progressively as women age.
Fibromodulin: A small extracellular matrix protein that helps organize collagen and regulate growth factor signaling, which decreases with age.
The team synthesized these changes into a 26-protein consensus panel called the Buck Postmenopausal Ovary Molecular Signature (BuckPOMS), which closely tracks chronological age.
Normal aging ovaries shared molecular traits with cellular senescence—where aging or damaged cells stop dividing but continue sending signals that affect nearby tissue—including Higher levels of secretory markers like TGM2, SAMP, AL1A2, and NAMPT. These healthy tissues also showed an enrichment of ovarian cancer-associated proteins, with peak scores concentrated in women aged 60–69—matching the typical age range for an ovarian cancer diagnosis.
TGM2 (Protein-glutamine gamma-glutamyltransferase 2): An enzyme that promotes tissue cross-linking and scarring during wound repair and fibrosis, which increases with age and is linked to cancer pathways.
SAMP (Serum amyloid P-component): An immune- and inflammation-related protein that increases with age and cellular senescence.
AL1A2 (Aldehyde dehydrogenase 1 family member A2): An enzyme involved in cellular metabolism and retinoid processing that increases with age and senescence-associated remodeling.
NAMPT (Nicotinamide phosphoribosyltransferase): A stress-response and metabolic enzyme linked to cellular aging and secretory pathways that increases with age.
Rethinking health risks post menopause
The findings present the postmenopausal ovaries as active tissue that may influence systemic aging and chronic disease.
“The ovary is not just a reproductive organ,” Schilling explained. “It really influences how somebody ages because it speaks to all these other organs, such as the brain, and also to the bone, and women after menopause often experience a lot of bone problems. So, we think there is a connection between all these organs.”
The shift toward a fibrotic and inflammatory protein profile suggests that the aging ovary builds a permissive, cancer-ready microenvironment. This insight informs clinical discussions regarding preventive oophorectomy, balancing cancer reduction against the long-term systemic risks of removing an active organ.
“It's not that all postmenopausal women get ovarian cancer, but we know that that fibrotic inflammatory environment is certainly an environment that cancer cells prefer to home in on,” Duncan added. “This is all consistent with the idea that the aging ovary is a potential third hit for ovarian cancer, with the first hit being genetic and the second hit being environmental. So can we target the aging ovary therapeutically to lower the risk of ovarian cancer, or can we develop novel biomarkers of ovarian cancer?”
“Our data points to progressive aging features in which the ovary appears to lose its original identity and ends up doing something different,” Duncan said. “We do not yet know if there's ever a point in a woman's life when this organ is no longer beneficial, and it's actually harmful. These results really point to the need to ask this question.”
Reference: Watson MA, Soygur B, King CD, et al. The human ovary exhibits dynamic molecular remodeling in the decades post-menopause. Aging Cell. 2026;25(10):e70714. doi: 10.1111/acel.70714
Original story: Northwestern University